Phanes Therapeutics announces FDA IND clearance for PT217, an anti-DLL3/anti-CD47 bispecific antibody being developed for patients with small cell lung cancer and other neuroendocrine cancers ...Middle East

SAN DIEGO, Oct. 14, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on oncology, announced today that it has received clearance from the US Food and Drug Administration (FDA) to commence Phase I studies with PT217, its anti-Delta-like...

Hence then, the article about phanes therapeutics announces fda ind clearance for pt217 an anti dll3 anti cd47 bispecific antibody being developed for patients with small cell lung cancer and other neuroendocrine cancers was published today ( Friday 14/10/2022 - 02:04 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phanes Therapeutics announces FDA IND clearance for PT217, an anti-DLL3/anti-CD47 bispecific antibody being developed for patients with small cell lung cancer and other neuroendocrine cancers )

Also on site :

• 13 US service members have died in the war with Iran. Here are their stories
• Is it illegal to park in a bike lane in Colorado?
• 2026 is a turning point for Africa